DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Stock Down 10.6 %

NASDAQ DBVT opened at $4.46 on Friday. The company has a market cap of $91.74 million, a price-to-earnings ratio of -0.99 and a beta of 0.71. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $8.32. The business’s fifty day moving average is $4.46 and its 200 day moving average is $3.84.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.